
    
      Objectives:

      (i) To evaluate the Safety and Performance of DuraGraftÂ®

      (ii) To characterize the use of DuraGraft and the outcomes of patients whose vascular grafts
      were treated with DuraGraft in daily clinical routine

      (iii) To further characterize the incidence of MACCE outcomes associated with CABG in
      patients whose vascular grafts were treated with DuraGraft in daily clinical routine

      (iv) To compare the use of DuraGraft among hospitals and practices

      (v) To obtain patient reported quality of life information

      (vi) To obtain important health economics outcomes
    
  